Results 191 to 200 of about 195,829 (332)

Deoxyribose analogues of N6‐cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo [PDF]

open access: green, 1995
Ron A. A. Mathôt   +4 more
openalex   +1 more source

Metal‐Ligand Complexes as Multifunctional Platforms for Photo‐Activated Cancer Therapy

open access: yesAdvanced Science, EarlyView.
Metal‐ligand complexes serve as multifunctional platforms for photo‐activated cancer therapy, facilitating photothermal and photodynamic effects through light absorption and reactive oxygen species generation. This review categorizes these complexes by ligand and metal types, examines their roles in combined therapeutic approaches, and explores ...
Jeonga Kim, Saehan Choi, Yoonsung Nam
wiley   +1 more source

Partial Agonist Activity of Neonicotinoids on Rat Nicotinic Receptors: Consequences over Epinephrine Secretion and In Vivo Blood Pressure. [PDF]

open access: yesInt J Mol Sci, 2021
Park J   +9 more
europepmc   +1 more source

Covalent Organic Frameworks‐Delivered Reuterin Drives Trained Immunity in Tumor‐Associated Macrophages to Enhance Melanoma Immunotherapy via Glycerophospholipid Metabolism

open access: yesAdvanced Science, EarlyView.
Covalent organic framework (COF)‐reuterin induces trained immunity in tumor‐associated macrophages, promoting the generation of nitric oxide and reactive oxygen species, thereby enhancing the antitumor immune response. Additionally, COF‐Reuterin directly kills tumor cells while simultaneously eradicating pathogenic intratumoural bacteria.
Jian‐Gang Zhang   +8 more
wiley   +1 more source

(+)‐WAY 100135, a partial agonist, at native and recombinant 5‐HT1B/1D receptors [PDF]

open access: green, 1997
Colin Davidson   +4 more
openalex   +1 more source

KRAS mRNA Spleen‐Targeting Lipid Nanoparticles Synergize with Irinotecan Silicasomes to Robustly Augment the Cancer Immunity Cycle in Pancreatic Cancer

open access: yesAdvanced Science, EarlyView.
To overcome pancreatic cancer's immunosuppressive barriers, this study explores a dual approach: triggering immunogenic tumor cell death at the primary tumor site with irinotecan‐loaded silicasomes and enhancing immune activation in the spleen using LNPs encapsulating tumor antigen mRNA and a TLR7/8 agonist.
Lijia Luo   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy